UnitedHealth Group hits fresh 52-week high, shares extend S&P 500 outperformance

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 11:45.

UnitedHealth Group (US91324P1021) has pushed to a fresh 52-week high around 416 US dollars on the NYSE this week, keeping the S&P 500 heavyweight firmly in focus for health-care investors. The move comes as Wall Street firms including BofA Securities and Leerink lift their price targets ahead of the next earnings release in mid-July.

What the latest high shows

According to a recent market commentary from Investing.com, UnitedHealth Group shares hit a new 52-week high at 416.04 US dollars, marking a 37.36 percent gain over the past twelve months. The same analysis cites a market capitalization of roughly 377 billion US dollars and annual revenue near 450 billion US dollars, with a reported revenue growth rate of about 9.7 percent.

On MarketScreener, the last regular NYSE close is shown at 415.53 US dollars, up 2.40 percent on the day and just below that new peak. With these levels, UnitedHealth Group remains one of the more heavily weighted names in the S&P 500 and the Dow Jones Industrial Average compared with peers like CVS Health and Elevance Health.

Analysts lift targets ahead of earnings

On 24 June, BofA Securities adjusted its price target for UnitedHealth Group to 475 US dollars from 450 US dollars, maintaining a positive stance on the stock according to MarketScreener's summary of recent analyst actions. Earlier in June, Leerink Partners raised its price target to 462 US dollars from 400 US dollars while reiterating an Outperform rating after reviewing margin prospects at the Optum Health division.

In addition, an analysis cited by Investing.com notes that Bernstein SocGen has reaffirmed an Outperform rating and set a 492 US dollar price target, again highlighting the Optum Health business as a key growth contributor. Taken together, these target moves describe a supportive consensus backdrop, even as individual houses differ on the exact upside they see for UnitedHealth Group shares.

Upcoming earnings date confirmed

UnitedHealth Group has already announced the date for its next earnings release via its investor relations channel, scheduling the second-quarter 2026 results for mid-July. MarketScreener lists this upcoming report as the next key event in the company calendar, following the recent annual shareholder meeting and board actions disclosed on 3 June.

The company last updated investors on the earnings release timing in mid-June, reinforcing the standard quarterly rhythm that many sell-side models now anchor to. For a large-cap health-care insurer in the S&P 500, this predictable cadence is central to how analysts structure their forecasts on premium trends, medical costs and Optum-related fee income.

How UnitedHealth Group earns its money

UnitedHealth Group generates the bulk of its revenue from health insurance premiums in the UnitedHealthcare segment and from health services through the Optum platform. UnitedHealthcare offers medical and dental benefit plans in the United States and internationally, covering employer-sponsored, individual, Medicare and Medicaid members.

Optum Health, Optum Insight and Optum Rx add fee-based care delivery, data analytics and pharmacy benefit management, giving the group exposure to both traditional insurance margins and broader health-care service trends. This diversified model differentiates UnitedHealth Group from some US peers that are more narrowly focused either on insurance or on pharmacy operations.

Where the shares trade today

The UnitedHealth Group shares (US91324P1021) last closed on the NYSE at 415.53 US dollars on 2026-06-25, 21:00, according to MarketScreener. That level values the company at roughly 377 billion US dollars based on the latest figures.

This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any financial instrument. Historical performance is not a reliable indicator of future results. Readers should conduct their own research and, where appropriate, consult a qualified financial advisor.